Glenzocimab:一种靶向GPVI(糖蛋白VI)的潜在抗血小板药物用于急性缺血性卒中治疗
本综述描述了抗GPVI抗体在缺血性卒中临床前模型中的治疗作用,并提供了Glenzocimab(人源化抗GPVI单克隆抗体的Fab片段)在卒中患者中的现有证据。Glenzocimab(125-1000 mg)在r-tPA再灌注后<3小时给药是安全的,1000 mg(选定剂量)未显著改善总体临床结局,但似乎在重症病例和需要取栓的患者中提供获益,良好的安全性特征支持进一步开展III期(ACTISAVE)临床研究。
要点
- 抗GPVI抗体JAQ1在小鼠短暂大脑中动脉闭塞模型中显著减小梗死体积并改善神经功能,无或仅有轻微出血倾向。
- Glenzocimab在非人灵长类中30分钟时完全抑制血小板聚集而不增加出血风险,在人体中耐受良好并产生剂量依赖性抗血小板活性。
- Glenzocimab 1000 mg未显著改善总体临床结局,但似乎在重症病例和需要取栓的患者中提供获益。
核心结论
- Glenzocimab(125-1000 mg)在急性缺血性卒中患者r-tPA再灌注后<3小时给药是安全的,1000 mg(选定剂量)未显著改善总体临床结局,但似乎在重症病例和需要取栓的患者中提供获益,值得进一步开展III期(ACTISAVE)临床研究。
研究设计与样本
- 综述,描述抗GPVI抗体在缺血性卒中临床前模型中的治疗作用,并提供Glenzocimab在卒中患者中的现有证据。
主要发现
- 抗GPVI抗体JAQ1在小鼠短暂大脑中动脉闭塞模型中显著减小梗死体积并改善神经功能,无或仅有轻微出血倾向。
- 非人灵长类静脉注射Glenzocimab后,对胶原(一种GPVI配体)诱导的离体血小板聚集产生快速抑制,给药后30分钟观察到完全血小板抑制而不增加出血风险。
- 在人体中,Glenzocimab耐受良好并产生剂量依赖性抗血小板活性。
- Glenzocimab(125-1000 mg)在急性缺血性卒中患者r-tPA再灌注后尽可能早(<3小时)给药是安全的。
- Glenzocimab 1000 mg(选定剂量)未显著改善总体临床结局,但似乎在重症病例和需要取栓的患者中提供获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has previously been shown in several animal experiments that platelet GPVI (glycoprotein VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are upregulated in stroke patients. This review describes the therapeutic roles of anti-GPVI antibody in preclinical models of ischemic stroke and provides the current evidence for potential benefits of glenzocimab, a Fab fragment of humanized anti-GPVI monoclonal antibody, in stroke patients. Anti-GPVI antibody, JAQ1, significantly decreased infarct volume and improved neurological function in mice with transient middle cerebral artery occlusion, a model of ischemic stroke, with no or minor bleeding tendency. Intravenous injection of glenzocimab in nonhuman primates produced rapid inhibition of ex vivo platelet aggregation induced by collagen (a GPVI ligand). Complete platelet inhibition is observed at 30 minutes following administration without increasing the risk of bleeding. In humans, glenzocimab is well tolerated and produces dose-dependent antiplatelet activity. More importantly, glenzocimab (125-1000 mg) was safe when administered as soon as possible (<3 hours) following reperfusion with the r-tPA (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke. Although glenzocimab 1000 mg (a selected dose) did not demonstrate a significant improvement in overall clinical outcomes, it appeared to provide benefits in severe cases and in patients who required thrombectomy. This promising efficacy together with a good safety profile of glenzocimab warrant further investigation in phase III (ACTISAVE [Adaptive Efficacy and Safety Study of Glenzocimab Used as an Add-On Therapy on Top of Standard of Care in the 4.5 Hours Following an Acute Ischemic Stroke]) clinical study.
引用
- Wichaiyo S, Parichatikanond W, Rattanavipanon W, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022. PMID: 36128904. doi:10.1161/STROKEAHA.122.039790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。